Selected endothelial progenitor cells and methods for use
AssigneeThe Board of Trustees of the University of Illinois
InventorsKishore K. Wary, Yidan Zhao, Asrar B. Malik, You-Yang Zhao
Life of this patent
Estimating the term…
Abstract
The present invention is a method for preparing a substantially pure population of endothelial progenitor cells wherein said cells express Flk-1, CD34, α5β1 integrin fibronectin, and vWF and exhibit an adherent phenotype and methods for using the same to decrease the severity of lung injury, prevent pulmonary edema, restore endothelial barrier function, induce productive wound healing and angiogenesis, and increase survival rate in acute lung injury (ALI).
Claims2
A method for decreasing severity of lung injury and preventing pulmonary edema in acute lung injury comprising
- culturing bone marrow derived mononuclear cells in the absence of epidermal growth factor and in the presence of vascular endothelial growth factor-121 and vascular endothelial growth factor-165;
- selecting adherent endothelial progenitor cells expressing fetal liver kinase 1 (Flk-1), CD34, α5β1 integrin, fibronectin and von Willebrand factor;
- and
- administering to the pulmonary vascular bed of a subject in need of treatment the selected adherent endothelial progenitor cells, thereby decreasing severity of lung injury and preventing pulmonary edema in the subject.
A method for increasing survival rate in acute lung injury comprising
- culturing bone marrow derived mononuclear cells in the absence of epidermal growth factor and in the presence of vascular endothelial growth factor-121 and vascular endothelial growth factor-165;
- selecting adherent endothelial progenitor cells expressing fetal liver kinase 1 (Flk-1), CD34, α5β1 integrin, fibronectin and von Willebrand factor;
- and
- administering to the pulmonary vascular bed of a subject in need of treatment the selected adherent endothelial progenitor cells, thereby increasing survival rate in the subject.
Dependencies are inferred from the claim text.